Scarica l'app Stockscreener
0.5668
0.56%
-0.0032
Dopo l'orario di chiusura:
.56
-0.0068
-1.20%
Precedente Chiudi:
$0.57
Aprire:
$0.5655
Volume 24 ore:
79,916
Relative Volume:
0.60
Capitalizzazione di mercato:
$21.87M
Reddito:
$7.88M
Utile/perdita netta:
$-69.20M
Rapporto P/E:
-0.2778
EPS:
-2.04
Flusso di cassa netto:
$-69.73M
1 W Prestazione:
-8.93%
1M Prestazione:
-11.10%
6M Prestazione:
-26.86%
1 anno Prestazione:
-34.47%
Intervallo 1D:
$0.5513
$0.585
Intervallo di 1 settimana:
$0.54
$0.6224
Portata 52W:
$0.54
$1.56
Bolt Biotherapeutics Inc Stock (BOLT) Company Profile
Nome
Bolt Biotherapeutics Inc
Settore
Industria
Telefono
650-665-9295
Indirizzo
900 CHESAPEAKE DRIVE, REDWOOD CITY
Confronta BOLT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| BOLT | 0.5668 | 21.87M | 7.88M | -69.20M | -69.73M | -2.04 |
| VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-03-02 | Iniziato | Guggenheim | Buy |
| 2021-03-02 | Iniziato | Morgan Stanley | Overweight |
| 2021-03-02 | Iniziato | SVB Leerink | Outperform |
| 2021-03-02 | Iniziato | Stifel | Buy |
Bolt Biotherapeutics Inc Borsa (BOLT) Ultime notizie
Bolt Biotherapeutics stock hits 52-week low at $0.54 By Investing.com - Investing.com Canada
Bolt Biotherapeutics stock hits 52-week low at $0.54 - Investing.com
HC Wainwright Issues Pessimistic Forecast for BOLT Earnings - Defense World
Bolt Biotherapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Bolt Biotherapeutics’ Restructuring Faces Potential Setbacks: A Closer Look - TipRanks
Bolt Biotherapeutics Reports Q3 2024 Financial Results - TipRanks
Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot - Houston Chronicle
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation - Yahoo Finance
BOLTBolt Biotherapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting - The Manila Times
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - Marketscreener.com
Bolt Biotherapeutics (STU:6LP) Cash Flow from Investing : €52.47 Mil (TTM As of Jun. 2024) - GuruFocus.com
Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
BOLT Stock Surges Over 5% Amidst Biotech Sector's Mixed Performa - GuruFocus.com
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances - Citeline
Bolt Biotherapeutics (BOLT) Stock Surges Amid Broad Biotech Indu - GuruFocus.com
Renaissance Technologies LLC Sells 240,898 Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) - Defense World
Renaissance Technologies LLC Has $208,000 Stock Holdings in Hesai Group (NASDAQ:HSAI) - Defense World
Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Drops By 39.1% - Defense World
Just Auto Excellence Awards 2024: TomTom - just-auto.com
Bolt Biotherapeutics (BOLT) Stock Surges Amid Biotech Sector Vol - GuruFocus.com
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Down 14.2% in September - Defense World
Bolt Biotherapeutics stock hits 52-week low at $0.61 By Investing.com - Investing.com Canada
Bolt Biotherapeutics stock hits 52-week low at $0.61 - Investing.com
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Significant Decrease in Short Interest - Defense World
Bolt Biotherapeutics stock hits 52-week low at $0.65 By Investing.com - Investing.com Australia
Bolt Biotherapeutics stock hits 52-week low at $0.65 - Investing.com
Bolt Biotherapeutics Announces Changes to its Board of Directors - ForexTV.com
Bolt Biotherapeutics reshuffles board, appoints new chair By Investing.com - Investing.com Canada
Bolt Biotherapeutics reshuffles board, appoints new director - Investing.com
Bolt Biotherapeutics Announces Board Reshuffle and New Appointment - TipRanks
Deadline on Sept. 3rd coming up in Lawsuit for Investors in shares of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) - openPR
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesBOLT - PR Newswire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the - EIN News
BOLT Investors Have the Opportunity to Lead Bolt - GlobeNewswire
BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Inc.
BOLT DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt - The Malaysian Reserve
BOLT Deadline: BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit - The Malaysian Reserve
BOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
BOLT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Finansavisen - Finansavisen
Bolt Biotherapeutics Inc Azioni (BOLT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
3.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):